Stryker’s SpineJack implantable fracture reduction system qualified for the Transitional Pass-Through (TPT) payment as part of the 2021 Medicare Hospital Outpatient Prospective Payment System. SpineJack is one of only 11 medical devices to receive TPT status since 2016.
The TPT payment provides additional payments for new medical devices that demonstrate a substantial clinical improvement over existing technologies.
The CMS TPT decision was based on both public commentary as well as findings from the SAKOS trial—a prospective, multicenter, randomized study designed to support a non-inferiority finding for use of the SpineJack System versus BKP in the treatment of painful osteoporotic VCFs.
“The CMS Transitional Pass-Through payment determination is a monumental step in providing a superior device technology in the treatment of osteoporotic vertebral compression fractures,” said Greg Siller, Vice President and General Manager of Stryker’s Interventional Spine business. “Due to the SpineJack System receiving both NTAP and TPT payment, physicians and administrators no longer have to make a decision between care and cost. We remain committed to offering innovative Interventional Spine solutions and working with our customers to improve patients’ lives.”
Stryker's SpineJack implantable fracture reduction system qualified for the Transitional Pass-Through (TPT) payment as part of the 2021 Medicare Hospital Outpatient Prospective Payment System. SpineJack is one of only 11 medical devices to receive TPT status since 2016.
The TPT payment provides additional payments for new medical devices...
Stryker’s SpineJack implantable fracture reduction system qualified for the Transitional Pass-Through (TPT) payment as part of the 2021 Medicare Hospital Outpatient Prospective Payment System. SpineJack is one of only 11 medical devices to receive TPT status since 2016.
The TPT payment provides additional payments for new medical devices that demonstrate a substantial clinical improvement over existing technologies.
The CMS TPT decision was based on both public commentary as well as findings from the SAKOS trial—a prospective, multicenter, randomized study designed to support a non-inferiority finding for use of the SpineJack System versus BKP in the treatment of painful osteoporotic VCFs.
“The CMS Transitional Pass-Through payment determination is a monumental step in providing a superior device technology in the treatment of osteoporotic vertebral compression fractures,” said Greg Siller, Vice President and General Manager of Stryker’s Interventional Spine business. “Due to the SpineJack System receiving both NTAP and TPT payment, physicians and administrators no longer have to make a decision between care and cost. We remain committed to offering innovative Interventional Spine solutions and working with our customers to improve patients’ lives.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
